MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

By sjmartinez • October 11, 2023

Crowell PD, Giafaglione JM, Jones AE, Nunley NM, Hashimoto T, Delcourt AML, Petcherski A, Agrawal R, Bernard MJ, Diaz JA, Heering KY, Huang RR, Low JY, Matulionis N, Navone NM, Ye H, Zoubeidi A, Christofk HR, Rettig MB, Reiter RE, Haffner MC, Boutros PC, Shirihai OS, Divakaruni AS, Goldstein AS. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Rep. 2023 Oct 9;42(10):113221. doi: 10.1016/j.celrep.2023.113221. Epub ahead of print. PMID: 37815914.

Tags: Cancer, CP, Endocrinology, Metabolism, Publications

Colliding crises: The global diabetes pandemic meets climate change-A scoping review

Perez JS, Hudson H, Araneta J, Bedell B, Aikins AD, Dugas LR, Eid M, Eshac Y, Fariduddin M, Fariduddin M, Jong K, Kapwata T, Luke[...]

Glymphatic system impairment in type II diabetes mellitus adults

Roy B, Lubera V, Singh KR, Singh A, Karunamuni DR, Kosoyan DE, Carrier M, Choi SE, Freeby MJ, Kumar R. Glymphatic system impairment in type[...]

Osilodrostat for Cyclic Cushing Disease

Rhyu J, Yu R. Osilodrostat for Cyclic Cushing Disease. AACE Endocrinol Diabetes. 2025 Sep 30;13(1):17-21. doi: 10.1016/j.aed.2025.09.011. PMID: 41641307; PMCID: PMC12866165.